Blocking immune checkpoint proteins from interacting with their binding partner proteins is a therapeutic strategy for directing the immune system to act against malignant cells. Immune checkpoint T cell immunoglobulin and ITIM domain (TIGIT) is an emerging target in cancer immunotherapy, and new studies on the localization, mechanism of action, and role of TIGIT in cancer will inform the development of new anti-cancer immunotherapies.
Download this TIGIT white paper to learn about:
- The role of immune checkpoints in cancer immunotherapy
- Inhibitory immune checkpoint receptor TIGIT
- TIGIT signaling related immune checkpoint markers
- IHC validated TIGIT recombinant antibodies
To access the download, please fill out this short form.
